vs
美敦力（MDT）与Smurfit Westrock（SW）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是Smurfit Westrock的1.2倍（$9.0B vs $7.7B），美敦力净利率更高（15.3% vs 0.8%，领先14.5%），美敦力同比增速更快（6.6% vs 0.7%），过去两年Smurfit Westrock的营收复合增速更高（61.2% vs 5.3%）
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
Smurfit Westrock plc是总部位于爱尔兰都柏林的企业，核心业务为生产瓦楞包装及各类纸制包装产品，公司股票同时在纽约证券交易所和伦敦证券交易所挂牌上市。
MDT vs SW — 直观对比
营收规模更大
MDT
是对方的1.2倍
$7.7B
营收增速更快
MDT
高出5.9%
0.7%
净利率更高
MDT
高出14.5%
0.8%
两年增速更快
SW
近两年复合增速
5.3%
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.0B | $7.7B |
| 净利润 | $1.4B | $63.0M |
| 毛利率 | 65.8% | 16.4% |
| 营业利润率 | 18.8% | 3.3% |
| 净利率 | 15.3% | 0.8% |
| 营收同比 | 6.6% | 0.7% |
| 净利润同比 | 8.2% | 0.0% |
| 每股收益（稀释后） | $1.07 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDTSW
| Q1 26 | — | $7.7B | ||
| Q4 25 | $9.0B | $7.6B | ||
| Q3 25 | $8.6B | $8.0B | ||
| Q2 25 | $8.9B | $7.9B | ||
| Q1 25 | $8.3B | $7.7B | ||
| Q4 24 | $8.4B | $7.5B | ||
| Q3 24 | $7.9B | $7.7B | ||
| Q2 24 | $8.6B | $3.0B |
净利润MDTSW
| Q1 26 | — | $63.0M | ||
| Q4 25 | $1.4B | $97.0M | ||
| Q3 25 | $1.0B | $246.0M | ||
| Q2 25 | $1.1B | $-28.0M | ||
| Q1 25 | $1.3B | $384.0M | ||
| Q4 24 | $1.3B | $146.0M | ||
| Q3 24 | $1.0B | $-150.0M | ||
| Q2 24 | $654.0M | $132.0M |
毛利率MDTSW
| Q1 26 | — | 16.4% | ||
| Q4 25 | 65.8% | 18.2% | ||
| Q3 25 | 65.0% | 19.6% | ||
| Q2 25 | 64.8% | 19.1% | ||
| Q1 25 | 66.5% | 20.6% | ||
| Q4 24 | 64.9% | 19.1% | ||
| Q3 24 | 65.1% | 17.6% | ||
| Q2 24 | 64.5% | 23.3% |
营业利润率MDTSW
| Q1 26 | — | 3.3% | ||
| Q4 25 | 18.8% | 5.1% | ||
| Q3 25 | 16.8% | 6.6% | ||
| Q2 25 | 16.1% | 3.2% | ||
| Q1 25 | 19.9% | 7.2% | ||
| Q4 24 | 19.0% | 5.3% | ||
| Q3 24 | 16.1% | 0.7% | ||
| Q2 24 | 12.3% | 8.2% |
净利率MDTSW
| Q1 26 | — | 0.8% | ||
| Q4 25 | 15.3% | 1.3% | ||
| Q3 25 | 12.1% | 3.1% | ||
| Q2 25 | 11.8% | -0.4% | ||
| Q1 25 | 15.6% | 5.0% | ||
| Q4 24 | 15.1% | 1.9% | ||
| Q3 24 | 13.2% | -2.0% | ||
| Q2 24 | 7.6% | 4.4% |
每股收益（稀释后）MDTSW
| Q1 26 | — | $0.12 | ||
| Q4 25 | $1.07 | $0.18 | ||
| Q3 25 | $0.81 | $0.47 | ||
| Q2 25 | $0.81 | $-0.05 | ||
| Q1 25 | $1.01 | $0.73 | ||
| Q4 24 | $0.99 | $-0.12 | ||
| Q3 24 | $0.80 | $-0.30 | ||
| Q2 24 | $0.50 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3B | — |
| 总债务越低越好 | $27.7B | $980.0M |
| 股东权益账面价值 | $48.7B | $18.1B |
| 总资产 | $91.3B | $45.2B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.05× |
8季度趋势，按日历期对齐
现金及短期投资MDTSW
| Q1 26 | — | — | ||
| Q4 25 | $8.3B | $892.0M | ||
| Q3 25 | $8.1B | $851.0M | ||
| Q2 25 | $9.0B | $778.0M | ||
| Q1 25 | $7.9B | $797.0M | ||
| Q4 24 | $8.0B | $855.0M | ||
| Q3 24 | $7.8B | — | ||
| Q2 24 | $8.0B | $26.8K |
总债务MDTSW
| Q1 26 | — | $980.0M | ||
| Q4 25 | $27.7B | $13.4B | ||
| Q3 25 | $26.2B | $13.3B | ||
| Q2 25 | $25.6B | $13.3B | ||
| Q1 25 | $24.0B | $12.9B | ||
| Q4 24 | $24.6B | $12.5B | ||
| Q3 24 | $26.3B | $13.2B | ||
| Q2 24 | $23.9B | — |
股东权益MDTSW
| Q1 26 | — | $18.1B | ||
| Q4 25 | $48.7B | $18.3B | ||
| Q3 25 | $47.9B | $18.4B | ||
| Q2 25 | $48.0B | $18.3B | ||
| Q1 25 | $49.4B | $17.9B | ||
| Q4 24 | $48.5B | $17.4B | ||
| Q3 24 | $47.9B | $18.0B | ||
| Q2 24 | $50.2B | $14.5K |
总资产MDTSW
| Q1 26 | — | $45.2B | ||
| Q4 25 | $91.3B | $45.2B | ||
| Q3 25 | $91.0B | $45.6B | ||
| Q2 25 | $91.7B | $45.7B | ||
| Q1 25 | $90.0B | $44.6B | ||
| Q4 24 | $90.0B | $43.8B | ||
| Q3 24 | $89.7B | $45.0B | ||
| Q2 24 | $90.0B | $26.8K |
负债/权益比MDTSW
| Q1 26 | — | 0.05× | ||
| Q4 25 | 0.57× | 0.73× | ||
| Q3 25 | 0.55× | 0.72× | ||
| Q2 25 | 0.53× | 0.73× | ||
| Q1 25 | 0.49× | 0.72× | ||
| Q4 24 | 0.51× | 0.72× | ||
| Q3 24 | 0.55× | 0.73× | ||
| Q2 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $925.0M | $204.0M |
| 自由现金流经营现金流 - 资本支出 | $457.0M | — |
| 自由现金流率自由现金流/营收 | 5.1% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | 0.67× | 3.24× |
| 过去12个月自由现金流最近4个季度 | $5.2B | — |
8季度趋势，按日历期对齐
经营现金流MDTSW
| Q1 26 | — | $204.0M | ||
| Q4 25 | $925.0M | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $2.5B | $829.0M | ||
| Q1 25 | $2.6B | $235.0M | ||
| Q4 24 | $958.0M | $781.0M | ||
| Q3 24 | $986.0M | $320.0M | ||
| Q2 24 | $2.8B | $340.0M |
自由现金流MDTSW
| Q1 26 | — | — | ||
| Q4 25 | $457.0M | $612.0M | ||
| Q3 25 | $584.0M | $523.0M | ||
| Q2 25 | $2.1B | $307.0M | ||
| Q1 25 | $2.1B | $-242.0M | ||
| Q4 24 | $554.0M | $212.0M | ||
| Q3 24 | $466.0M | $-192.0M | ||
| Q2 24 | $2.4B | $163.0M |
自由现金流率MDTSW
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | 8.1% | ||
| Q3 25 | 6.8% | 6.5% | ||
| Q2 25 | 23.2% | 3.9% | ||
| Q1 25 | 25.3% | -3.2% | ||
| Q4 24 | 6.6% | 2.8% | ||
| Q3 24 | 5.9% | -2.5% | ||
| Q2 24 | 27.4% | 5.5% |
资本支出强度MDTSW
| Q1 26 | — | — | ||
| Q4 25 | 5.2% | 7.7% | ||
| Q3 25 | 5.9% | 7.6% | ||
| Q2 25 | 5.1% | 6.6% | ||
| Q1 25 | 5.7% | 6.2% | ||
| Q4 24 | 4.8% | 7.5% | ||
| Q3 24 | 6.6% | 6.7% | ||
| Q2 24 | 5.0% | 6.0% |
现金转化率MDTSW
| Q1 26 | — | 3.24× | ||
| Q4 25 | 0.67× | 12.32× | ||
| Q3 25 | 1.05× | 4.61× | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.99× | 0.61× | ||
| Q4 24 | 0.75× | 5.35× | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 4.25× | 2.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
SW
暂无分部数据
